Growing Autoimmune Disease Market
The global autoimmune disease market continues to expand, with over 100 million patients across 80+ indications. Existing therapies, face limitations such as limited response, high recurrence rates, and immunogenicity concerns leading to treatment resistance.
We are developing next-generation therapeutics designed to deliver superior and sustained efficacy for patients.
Unmet Needs
Current antibody drugs for autoimmune diseases present a high risk of anti-drug antibody (ADA) responses, reducing long term efficacy and increasing infection risk. Combination therapies and bispecific antibodies have struggled due to immunogenicity concerns and clinical failures, while JAK inhibitors carry black box warnings for severe side effects.
We aim to address these challenges by designing our therapies to have enhanced target selectivity and lower immunogenicity than available therapies.
Our Goal
We are committed to discovering and developing first-in-class and best-in-class therapeutics for autoimmune diseases, targeting areas of significant unmet medical need. Built on a strong scientific foundation and driven by innovation, we are actively exploring strategic licensing and collaboration opportunities. At the same time, we aim to build a pipeline with blockbuster potential and advance it toward global development and commercialization.
